@article {1, editor = {,}, title = {New drugs for peripheral joint psoriatic arthritis}, volume = {44}, number = {1}, pages = {1--5}, year = {2006}, doi = {10.1136/dtb.2006.4411}, publisher = {British Medical Journal Publishing Group}, abstract = {Relevant BNF section: 10.1Up to 3\% of people have psoriasis, and as many as 42\% of these have an associated chronic inflammatory arthritis.1 In up to 20\% of such patients, the arthritis progresses to become severe, destructive and deforming.2{\textendash}5 Traditional drug treatments include NSAIDs and disease-modifying anti-rheumatic drugs (DMARDs) used for rheumatoid arthritis. ▼Leflunomide (Arava - Sanofi-Aventis), ▼etanercept (Enbrel - Wyeth) ▼inifliximab (Remicade - Schering-Plough) and ▼adalimumab (Humira - Abbott) are licensed for the treatment of patients with peripheral joint disease in psoriatic arthritis. Here we review drug therapy for such patients, concentrating on the newer agents.}, issn = {0012-6543}, URL = {https://dtb.bmj.com/content/44/1/1}, eprint = {https://dtb.bmj.com/content/44/1/1.full.pdf}, journal = {Drug and Therapeutics Bulletin} }